Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cendrine Tourette

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Journal of the American Geriatrics Society|April 21, 2018
Retrospective Evaluation of a Restrictive Transfusion Strategy in Older Adults with Hip FractureLorene Zerah, Lucile Dourthe, Judith Cohen-Bittan, et al.
BMC Geriatrics|August 4, 2025
Characterizing sarcopenia and sarcopenic obesity in patients aged 65 years and over, at risk of mobility disability: a multicenter observational trial (SARA-OBS)Roger A Fielding, Yves Rolland, Olivier Bruyere, et al.
Antioxidants (Basel, Switzerland)|May 28, 2022
Identification of Modulators of the <i>C.</i> <i>elegans</i> Aryl Hydrocarbon Receptor and Characterization of Transcriptomic and Metabolic AhR-1 ProfilesLucie Larigot, Linh-Chi Bui, Marine de Bouvier, et al.
Plos Biology|June 25, 2014
The Wnt receptor Ryk reduces neuronal and cell survival capacity by repressing FOXO activity during the early phases of mutant huntingtin pathogenicityCendrine Tourette, Francesca Farina, Rafael P Vazquez-Manrique, et al.
Journal of Cachexia, Sarcopenia and Muscle|March 3, 2025
BIO101 in Sarcopenic Seniors at Risk of Mobility Disability: Results of a Double-Blind Randomised Interventional Phase 2b TrialRoger A Fielding, Michael M Dao, Kevin Cannon, et al.
Eclinicalmedicine|March 28, 2024
Efficacy of oral 20-hydroxyecdysone (BIO101), a MAS receptor activator, in adults with severe COVID-19 (COVA): a randomized, placebo-controlled, phase 2/3 trialSuzana Margareth Lobo, Gaétan Plantefève, Girish Nair, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Journal of the American Geriatrics Society|April 21, 2018
Retrospective Evaluation of a Restrictive Transfusion Strategy in Older Adults with Hip FractureLorene Zerah, Lucile Dourthe, Judith Cohen-Bittan, et al.
BMC Geriatrics|August 4, 2025
Characterizing sarcopenia and sarcopenic obesity in patients aged 65 years and over, at risk of mobility disability: a multicenter observational trial (SARA-OBS)Roger A Fielding, Yves Rolland, Olivier Bruyere, et al.
Antioxidants (Basel, Switzerland)|May 28, 2022
Identification of Modulators of the <i>C.</i> <i>elegans</i> Aryl Hydrocarbon Receptor and Characterization of Transcriptomic and Metabolic AhR-1 ProfilesLucie Larigot, Linh-Chi Bui, Marine de Bouvier, et al.
Plos Biology|June 25, 2014
The Wnt receptor Ryk reduces neuronal and cell survival capacity by repressing FOXO activity during the early phases of mutant huntingtin pathogenicityCendrine Tourette, Francesca Farina, Rafael P Vazquez-Manrique, et al.
Journal of Cachexia, Sarcopenia and Muscle|March 3, 2025
BIO101 in Sarcopenic Seniors at Risk of Mobility Disability: Results of a Double-Blind Randomised Interventional Phase 2b TrialRoger A Fielding, Michael M Dao, Kevin Cannon, et al.
Eclinicalmedicine|March 28, 2024
Efficacy of oral 20-hydroxyecdysone (BIO101), a MAS receptor activator, in adults with severe COVID-19 (COVA): a randomized, placebo-controlled, phase 2/3 trialSuzana Margareth Lobo, Gaétan Plantefève, Girish Nair, et al.
Pageof 2